The companies will ensure that patients enrolled in the ongoing Phase II study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and Wyeth do not expect to continue to collaborate on future development of hepatitis C treatment candidates.
Vincent Milano, president and CEO of ViroPharma, said: “Significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development.”